Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Spherix Global Insights
< Previous
1
2
3
4
Next >
First Look at Roche/Genentech’s Gazyva Shows Strong Early Enthusiasm in Lupus Nephritis Launch, According to Spherix Global Insights
November 19, 2025
From
Spherix Global Insights
Via
GlobeNewswire
Spherix Global Insights Reports Rapidly Evolving U.S. PNH Market as Ultomiris Prescriptions Reach Parity with Iron Supplements
November 19, 2025
From
Spherix Global Insights
Via
GlobeNewswire
UCB’s Bimzelx and AbbVie’s Rinvoq Lead in EU5 Psoriatic Arthritis, Ankylosing Spondylitis, and Non-Radiographic Axial Spondyloarthritis Growth
November 13, 2025
From
Spherix Global Insights
Via
GlobeNewswire
Spherix Global Insights Reveals Unmet Need Driving Interest in Emerging Therapies for Thyroid Eye Disease
November 12, 2025
From
Spherix Global Insights
Via
GlobeNewswire
Novel Pipeline Activity Signals Hope in Systemic Sclerosis, as Rheumatologists Anticipate First Real Therapeutic Advances in Years
November 06, 2025
From
Spherix Global Insights
Via
GlobeNewswire
Gene and Cell Therapies Emerge as Front-Runners in Neurology Innovation, with High Expectations in ALS, Parkinson’s, and Neuroimmune Disorders
November 03, 2025
From
Spherix Global Insights
Via
GlobeNewswire
Spherix Global Insights Launches Market Dynamix™: PD-1 Inhibition in Solid Tumors, Delivering a Comprehensive Assessment of Biosimilar and Subcutaneous PD-1 Market Dynamics Across Key Oncology Indications
October 31, 2025
From
Spherix Global Insights
Via
GlobeNewswire
Targeted Biologics Expand in Early-Line gMG Treatment as New Entrants Prepare to Challenge Established Leaders
October 29, 2025
From
Spherix Global Insights
Via
GlobeNewswire
Step Therapy Shifts and Pipeline Momentum Reshape the Membranous Nephropathy Treatment Landscape, according to Spherix Global Insights
October 28, 2025
From
Spherix Global Insights
Via
GlobeNewswire
Evolving Treatment Landscape for Chronic Spontaneous Urticaria Highlights Significant Unmet Needs and Expanding Opportunities for Therapeutic Innovation
October 24, 2025
From
Spherix Global Insights
Via
GlobeNewswire
Hemophilia Specialists Raise the Bar: Quality of Life and Innovation Drive Market Reordering
October 22, 2025
From
Spherix Global Insights
Via
GlobeNewswire
Sjögren’s Disease Remains an Underdiagnosed and Underguided Condition, Creating an Opening for Manufacturers to Shape the Future of Care, According to Spherix Global Insights
October 16, 2025
From
Spherix Global Insights
Via
GlobeNewswire
Spherix Global Insights Expands Hematology Franchise to Include Oncology, Enhancing Advisory Services and Delivering Deeper Physician and Market Insights
October 15, 2025
From
Spherix Global Insights
Via
GlobeNewswire
Spherix Global Insights Identifies Emerging Trends in Market Access Across More Than Twenty Key Therapeutic Areas
October 14, 2025
From
Spherix Global Insights
Via
GlobeNewswire
Priovant’s Brepocitinib Poised to Address Steroid-Sparing Gap in Dermatomyositis as Rheumatologists Anticipate 2026 Launch
October 10, 2025
From
Spherix Global Insights
Via
GlobeNewswire
US Rheumatologists View Cell Therapy as a Potential Game Changer, with Systemic Sclerosis Emerging as the Most Compelling Indication, According to Spherix Global Insights
October 06, 2025
From
Spherix Global Insights
Via
GlobeNewswire
Physicians Signal Cautious Enthusiasm for Gene Therapy Across Hematology, But Adoption Remains Selective
October 02, 2025
From
Spherix Global Insights
Via
GlobeNewswire
Spherix Global Insights Highlights Patient Influence in Shaping PNH Treatment Choices
September 26, 2025
From
Spherix Global Insights
Via
GlobeNewswire
As Roche/Genentech’s Obinutuzumab (Gazyva) Nears FDA Decision, Spherix Global Insights White Paper Reveals Keys to Successful Lupus Product Launches
October 02, 2025
From
Spherix Global Insights
Via
GlobeNewswire
AbbVie’s Rinvoq Gains Early Traction in Giant Cell Arteritis Market, Expanding Options for Rheumatologists
September 25, 2025
From
Spherix Global Insights
Via
GlobeNewswire
Gene and Oral Therapies Drive Urgency and Innovation in Retinal Care, Reshaping Ophthalmology’s Future, According to Spherix Global Insights
August 28, 2025
From
Spherix Global Insights
Via
GlobeNewswire
Despite Early Low Awareness, Physicians Forecast Swift Adoption of Novo Nordisk’s Wegovy in MASH, According to Spherix Global Insights
August 28, 2025
From
Spherix Global Insights
Via
GlobeNewswire
Patient-Led Decisions Accelerate IBD Treatment Switching, Spherix Global Insights Finds
August 26, 2025
From
Spherix Global Insights
Via
GlobeNewswire
US Rheumatologists Point to Difficult-to-Treat populations, Oral Delivery, and Novel Mechanisms as the Key Drivers of Future RA Treatment Evolution, According to Spherix Global Insights
August 25, 2025
From
Spherix Global Insights
Via
GlobeNewswire
Critical Inflection Point in FSGS on the Horizon with Nephrologists Poised to Rapidly Adopt New Therapies, According to Spherix Global Insights
August 21, 2025
From
Spherix Global Insights
Via
GlobeNewswire
Spherix Global Insights Announces Upcoming New Special Topix™ Unpacking Payer Management Strategies Across Over 25 Therapeutic Areas
August 19, 2025
From
Spherix Global Insights
Via
GlobeNewswire
Which Gene Therapy Technology Wins? New Data from Spherix Global Insights Reveals Emerging Hematologist Preferences in Beta Thalassemia Care
August 14, 2025
From
Spherix Global Insights
Via
GlobeNewswire
Rheumatologists Eagerly Anticipate Pipeline Advancements in Idiopathic Inflammatory Myopathies to Address Deep Unmet Need, According to Spherix Global Insights
August 07, 2025
From
Spherix Global Insights
Via
GlobeNewswire
Johnson & Johnson Innovative Medicine’s Tremfya Gains Momentum in Crohn’s Disease, Outpacing Eli Lilly’s Omvoh and Challenging AbbVie’s Skyrizi
August 06, 2025
From
Spherix Global Insights
Via
GlobeNewswire
Beyond Gene Therapy: Pyruvate Kinase Activators (Agios, Novo Nordisk) Offer a New Route to Address Hemoglobin, VOCs, and Transfusion Burden in Sickle Cell Disease
August 06, 2025
From
Spherix Global Insights
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.